In vitro maturation of human immature oocytes for fertility preservation
Pregnancies achieved after cryopreservation of in vitro and in vivo matured oocytes are not associated with adverse pregnancy outcomes and may represent a novel strategy of fertility preservation.
Ri-Cheng Chian, Ph.D., Peter S. Uzelac, M.D., Geeta Garnund, M.D.
Volume 99, Issue 5, Pages 1173-1181, April 2013
Cryopreservation of embryos, oocytes and ovarian tissues are the three main options for female fertility preservation. Oocyte cryopreservation is emerging as an especially important can be considered one of important interventionoptions due to the recent dramatic remarkably increase in thed number of infant born from the vitrified oocytes recently. However, oocyte cryopreservation with the ‘standard controlled ovarian hyperstimulation (COH) may not be feasible for some cancer patients;, becaus there are serious concerns about the effect of ovarian stimulation with hormones on the risk of cance recurrence andor there mayis not be enough time to undergo hormonal ovarian stimulation befor gonadotoxic cancer treatment. Alternatively, immature oocyte retrieval from ovaries without ovarian stimulation followed by in vitro maturation (IVM) and vitrification can be provided a promising fertility preservation option for those women who are unable to undergo ovarian stimulation and who cannot be delayed the gonadotoxic cancer treatment. Immature oocytes can be collected from the ovaries in both the follicular phase and the vluteal phase that would maximize the possibility for the fertility preservation. The combination of ovarian tissue cryopreservation with immature oocytes collection from the tissue followed by IVM-vitrification of oocytes represents another promising approach of fertility preservation for young women with cancers.